Redhill Biopharma Ltd (STU:2RH0)
€ 0.431 0.029 (7.21%) Market Cap: 13.74 Mil Enterprise Value: 9.70 Mil PE Ratio: 0 PB Ratio: 4.52 GF Score: 50/100

Q3 2019 Redhill Biopharma Ltd Earnings Call Transcript

Nov 19, 2019 / 01:30PM GMT
Release Date Price: €218 (-3.54%)
Operator

Good day, and welcome to the RedHill's Biopharma Third Quarter 2019 Financial Results and Operational Highlights Conference Call.

At this time, I would like to introduce to the conference call RedHill's CEO, Mr. Dror Ben-Asher; Mr. Micha Ben-Chorin, RedHill's CFO; Mr. Gilead Raday, RedHill's Chief Operating Officer; Mr. Guy Goldberg, RedHill's Chief Business Officer; and Mr. Rick Scruggs, RedHill's Chief Operating Officer, U.S. operations. (Operator Instructions)

Before we begin, we will read from RedHill's safe harbor statement. Please go ahead.

Unidentified Company Representative

This conference call may contain projections or other forward-looking statements regarding future events or the future performance of RedHill, including statements with respect to RedHill's expectations regarding the initiation, timing, progress and results of its research, manufacturing, preclinical studies, clinical trials, marketing application or approvals, if any, other therapeutic candidate development efforts and the timing of the commercial launch of Aemcolo and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot